

AMENDMENTS TO THE CLAIMS

Please amend the claims as shown.

1-49. (Canceled).

50. (New) A composition for affecting weight loss comprising a weight loss affecting amount of a combination of:

(a) naltrexone or a pharmaceutically acceptable salt thereof; and

(b) a sustained release formulation of bupropion or a pharmaceutically acceptable salt thereof;

wherein said composition is formulated for oral administration.

51. (New) The composition of claim 50, wherein said combination comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof.

52. (New) The composition of claim 50, wherein said combination comprises about 30 mg to about 300 mg of bupropion or a pharmaceutically acceptable salt thereof.

53. (New) The composition of claim 50, wherein said combination comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof, and about 30 mg to about 300 mg of bupropion or a pharmaceutically acceptable salt thereof.

54. (New) The composition of claim 50, further comprising zonisamide or a pharmaceutically acceptable salt thereof.

55. (New) A pharmaceutical composition for affecting weight loss comprising a weight loss affecting amount of a combination of:

(a) naltrexone or a pharmaceutically acceptable salt thereof; and

(b) a sustained release formulation of bupropion or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable excipient, diluent, or carrier, wherein said composition is formulated for oral administration.

56. (New) The pharmaceutical composition of claim 55, wherein said combination comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof.

57. (New) The pharmaceutical composition of claim 55, wherein said combination comprises about 30 mg to about 300 mg of bupropion or a pharmaceutically acceptable salt thereof.

58. (New) The pharmaceutical composition of claim 55, wherein said combination comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof, and about 30 mg to about 300 mg of bupropion or a pharmaceutically acceptable salt thereof.

59. (New) The composition of claim 55, further comprising zonisamide or a pharmaceutically acceptable salt thereof.

60. (New, Withdrawn) A method of affecting weight loss comprising identifying an individual in need thereof and treating said individual by administering a composition according to claim 50.

61. (New, Withdrawn) The method of claim 60, wherein said individual has a body mass index greater than 25.

62. (New, Withdrawn) The method of claim 60, wherein said individual is not suffering from depression.

63. (New, Withdrawn) A method of increasing satiety in an individual comprising identifying an individual in need thereof and treating said individual by administering a composition according to claim 50.

64. (New, Withdrawn) The method of claim 63, wherein said individual is not suffering from depression.

65. (New, Withdrawn) A method of suppressing the appetite of an individual comprising identifying an individual in need thereof and treating said individual by administering a composition according to claim 50.

66. (New, Withdrawn) The method of claim 65, wherein said individual is not suffering from depression.